drugset / Trial / NCT00349557
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).
Timeline
- Start
- 2006-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Bicalutamide | Other / unclassified | — | — |
| Subject | Goserelin | Other / unclassified | — | — |